natgillin/translations-raw huggingface dataset:
ii) a second OspA fragment (also referred to as a second OspA portion) consisting of amino acids 177-274 of OspA from B. garinii, strain PBr (SEQ ID NO: 8), wherein the second OspA fragment differs from the corresponding wild-type sequence by the substitution of the wild-type amino acid at position 182 of SEQ ID NO: 8 by a cysteine and by the substitution of the wild-type amino acid at position 269 of SEQ ID NO: 8 and wherein a disulfide bond between the cysteine at position 182 and the cysteine at position 269 of said second OspA fragment is present; and wherein the numbering of the cysteine substitutions is according to the numbering of corresponding amino acids of the full length OspA of B. burgdorferi s.s., strain B31 (SEQ ID NO: 5). 
aminokiseline 177-274 od OspA iz B. garinii soja, PBr (SEQ ID NO: 8), sa supstitucijom treonina s ostatkom aminokiselini 233 sa ostatkom prolina, pri čemu je drugi OspA fragment mutant i cistin stabiliziran time što se razlikuje od odgovarajuće sekvenca divljeg tipa supstituiran barem aminokiselinom divljeg tipa na položaju 182 +/- 3 od SEQ ID NO: 8 pomoću cisteina i supstitucijom aminokiseline divljeg tipa na položaju 269 +/- 3 od SEQ ID NO: 8 pomoću cistein 1 gdje je disulfidna veza između cisteina na položaju 182 +/- 3 1 cisteina na položaju 269 +/- 3 navedenog drugog OspA fragmenta; i pri čemu je numeriranje aminokiselina 1 cisteinskih supstitucija u skladu s numeracijom odgovarajućih aminokiselina pune dužine OspA od B. burgdorferi s.s. soja B31 (SEQ ID NO: 5).
EPMATHMARKEREP where A is the rate of animals with thrombotic occlusion in treated group; and B is the rate of animals with thrombotic occlusion in the control group 
Frakcijska inhibicija = (1-A/B) x 100 gdje A je broj životinja s tromboznom okluzijom u liječenoj skupini; i B je broj životinja s tromboznom okluzijom u kontrolnoj skupini.
treating the trans-amino acid derivative of formula I or formula II, or a salt thereof with a reducing agent to give asenapine of formula A; and 
obradi trans-aminokiselinskog derivata formule I ili formule II [image] ili njegove soli reducenskom kako bi se dobilo asenapin formule A; i
The process of claim 13, further comprising: washing said SIA with PBS; and 
pranje navedenog SIA s PBS-om; i resuspendiranje navedenog SIA u PBS-u.
a protein-binding segment that interacts with a Cas9 protein, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, and wherein said two complementary stretches of nucleotides are covalently linked by intervening nucleotides. 
(ii) segment koji veže protein i koji međudjeluje s navedenim kimernim proteinom Cas9, pri čemu segment koji veže protein obuhvaća dva komplementarna odsjeka nukleotida koji hibridiziraju za tvorbu dvostruke RNK strukture (AdsRNK)-dupleks, gdje se navadeno stavljanje u doticaj provodi in vitro ili u stanici ex vivo.
The fan assembly of claim 1, wherein the first member comprises an air pipe for receiving the air flow. 
Ventilatorski sustav prema zahtjevu 2 ili zahtjevu 3, gdje prvi član (304) ima zračnu cijev za primanje struje zraka.
The composition of any of claims 1-4, wherein 19% to 28% of the polypeptides in the mixture have diethylamide at one end thereof. 
Sastav prema bilo kojem od patentnih zahtjeva 1 - 4, naznačen time, da 19% do 28% polipeptida u smjesi imaju dietilamid na jednom njihovom kraju.
and R2 a substituted or unsubstituted phenyl. 
ž i R? je supstituiran ili nesupstituiran fenil.
[8B-5] a C1-5 alkoxy group which may be substituted by 1-2 substituent(s) selected from the group consisting of [1] a C1-3 alkoxy group and [2] a C3-6 cycloalkyl group, 
<4> Cia alkanoilna skupina, koja može biti supstituirana s jednim ili više supstituenata, koje se bira iz skupine koju čine [1] skupina (C1.g alkil),ygka-amino i [2] atom halogena, mš8k4: 0-2,
and R6 together with the carbon they are bonded to form 1-chloro-1-methoxycarbonyl-cyclopropyl, cyclopropyl, 1,1-dichlorocyclopropyl, nitro-cyclopropyl, phenylcarbonyl-cyclopropyl, propen-2-yl-cyclopropyl, or vinyl-cyclopropyl, or 
R* i R* zajedno s atomom ugljika na koji su povezani tvore 1-klor-1-metoksikarbonil-ciklopropil, ciklopropil, 1,1-diklorciklopropil, nitro-ciklopropil, fenilkarbonil-ciklopropil, propen-2-il-ciklopropil, ili vinil-ciklopropil, ili
optionally containing 1 to 3 carbonyl, sulfinyl, or sulfonyl groups in the ring, and RT1 represents hydrogen or C1-6 alkyl; and wherein Substituent Group C consists of halogen, hydroxyl, mercapto, nitro, cyano, oxo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl representing a mono- or di-cyclic saturated aliphatic hydrocarbon group with 3 to 10 carbon atoms, C6-10 aryl, 5- to 10-membered heteroaryl, a 3- to 10-membered non-aromatic heterocyclic group representing 
Ci alkil, C2g alkenil, C2g alkinil ili skupinu prikazanu sa formulom -CO-R'", pri čemu R'? ima isto značenje kako je gore navedeno; pri čemu supstitucijska skupina A sadrži halogen, hidroksil, merkapto, nitro, cijano i okso; pri čemu supstitucijska skupina B sadrži C,.4 alkil, C2g4 alkenil, C24 alkinil, Ca_jocikloalkil koji predstavlja mono- ili bicikličku zasićenu alifatsku skupinu ugljikovodika sa 3 do 10 atoma ugljika, C4_19 aril, 5- do 10-člani heteroaril, 3- do 10-članu ne-aromatsku heterocikličnu skupinu koja
In certain such embodiments, the density of the extended release matrix formulation is equal to or less than about 1.19 g/cm3, preferably equal to or less than about 1.18 g/cm3 or equal to or less than about 1.17 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 13, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm?, poželjno jednaka ili manja od oko 1.19 g/em'.
an antibody that recognises simultaneously the C-terminal region of both AB40 and AB42 and 
protutijelo koje istodobno prepoznaje C-terminalno područje i kod AB40 i kod AB42 i
According to another aspect of the invention, there is provided the use of a compound of formula (I) or a physiologically acceptable solvate thereof for the manufacture of a medicament for the treatment of patients with inflammatory and/or allergic conditions. 
Upotreba spoja formule (1), ili njegovog fiziološki prihvatljivog solvata, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što navedeni spoj je namijenjen proizvodnji medikamenta za liječenje upalnih i/ili alergijskih stanja.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more pharmaceutically acceptable carriers, diluents and excipients. 
Farmaceutski sastav obuhvaća terapijski učinkovitu količinu tvari iz patentnog zahtjeva 1 1 jedan ili više farmaceutski prihvatljivih nosača, diluenata i ekscipijenasa.
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, or COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl); and salts thereof; 
Ru je vodik, C, do Cg alkil, fenil nesupstituiran ili supstituiran s C, do Cg alkilom, COR; acilnom skupinom (Rs je vodik; C; do Cg ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C, do C4 alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli.
The method of claim 7, wherein the Mucopolysaccharidosis is MPS I, II, IIIA, IIIB, IIIC, IIID, IVA, IVB, VI, or VII. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je mukopolisaharidoza MPS I, II, IIIA, IIIB, IIIC, IIID, IVA, IVB, VI ili VII.
pH-independent insoluble polymers such as ethylcellulose polymers or ethyl acrylate methyl methacrylate copolymer,and 
pH-neovisnih netopljivih polimera kao što su polimeri etilceluloze ili kopolimer etil akrilata i metil metakrilata, i
The molecule of para. 22, wherein the activated B chain has a conformation of B chain obtained by cleavage of single chain HGF. 
Molekula prema zahtjevu 25, naznačena time, da aktivirani B lanac ima konformaciju f lanca dobivenog cijepanjem jednolančanog HGF.
The precipitation of a white solid corresponding to the disulfide (2) is observed during the reaction. 
Tijekom reakcije opaža se istaloženu bijelu krutu tvar koja odgovara disulfidu (2).
washing the aqueous layer with an organic solvent; and 
ispiranja vodenog sloja organskim otapalom; i
by complexing with urea, followed by isolation and discharging of saturated and monounsaturated components, or by other methods. 
kompleksiranjem s ureom, nakon čega slijedi izolacija 1 odbacivanje zasićenih i mononezasićenih komponenata, ili drugim postupcima.
A delayed release drug formulation according to aspect #2, wherein at least 10%, preferably at least 25%, more preferably at least 50%, and most preferably at least 90%, of the carboxylic acid groups of said polycarboxylic acid polymer are in the form carboxylate anions. 
Polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 90 % skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku anjona karboksilata. Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u patentnom zahtjevu 1 ili patentnom zahtjevu 2, pri čemu je treći polimerni materijal potpuno neutraliziran.
The cell according to claim 7, wherein the electrode compartment is part of a refreshing system with a reserve container for an emulsion and a storage container for used emulsion, conduits to connect each of the containers with the electrode compartment and a transport unit, for example a pump, to move the emulsion. 
Odjeljak elektrode sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je ovaj dio sustava za osvježavanje s rezervnim spremnikom za emulziju i spremnikom za skladištenje iskorištene emulzije, cijevi za spajanje svakog spremnika s odjeljkom elektrode, na primjer crpke, za pomicanje emulzije.
of isolating the compound of the Formula IIa. 
[image] iz spoja sa formulom X:
v)—A mixture of methyl lithium (1.4 M solution in diethyl ether, 475 ml) and dry THF (5000 ml) was cooled to −40° C. A solution of the product obtained in the previous step (54 g) in dry THF (1000 ml) was added and the reaction mixture was stirred at room temperature overnight. 
- Smjesu metillitija (1,4 M otopina u dietil-eteru, 475 ml) i suhom THF (5000 ml) ohladi se do -40 *C. Doda se otopina produkta dobivenog u prethodnom koraku (54 g) u suhom THF (1000 ml), a reakcijsku smjesu miješa preko noći na sobnoj temperaturi.
The rock bolting system as claimed in claim 2, characterized in that the connection sleeve (8) comprises abutment means, against which a rock plate (14) may abut. 
Sistem sidrenja u stijeni prema patentnom zahtjevu 2, naznačen time, da vezni rukavac (8) sadrži sredstvo o koje se ploča uz stijenu (14) može uprijeti.
The compound of claim 2, wherein the compound is characterized by one or more of the following features: 
Spoj prema zahtjevu 2, pri čemu je spoj naznačen time što ima jednu ili više od slijedećih značajki:
The cell according to claim 21, wherein said cell is mammalian. 
Stanica prema patentnom zahtjevu 13, pri čemu je navedena stanica bakterijska stanica ili stanica sisavca.
The present invention provides compounds of the formula I 
Spojevi opće formule naznačeni time, da je R' skupina
means (711) for building a signal frame comprising preamble symbols based on the frequency interleaved constellation values, wherein the preamble symbols are divided into Layer 1 blocks and each Layer 1 block has 3408 subcarriers. The transmitter of claim 1, wherein the FEC encoder comprises: 
graditelj okvira (711) konfiguriran za izgradnju okvira signala koji obuhvaća simbole početnog niza temeljene na konstelacijskim vrijednostima s umetnutim frekvencijama koje odgovaraju signalnom podatku razine 1 i zaglavlju razine 1, pri čemu su simboli početnog niza podijeljeni u blokove razine 1 i svaki blok razine 1 ima 3408 podnosača; i modulator (712, 713) konfiguriran za izvođenje inverzne brze Fourierove transformacije i umetanje intervala čuvara u emitirani signal uključujući okvir signala.
receiving a selection of a second of the Internet addresses from the list of the Internet addresses from another of the widgets; 
- < povezivanje jedne ili više oznaka (,,yyy') s navedenim internetskim adresama ili s navedenim dodanim internetskim adresama;
The composition as claimed in claim 4 formulated in the form of soft gelatin capsules or cellulose capsules to contain oil substances. 
Pripravci kako su navedeni u patentnom zahtjevu 6, naznačeni time da su u obliku mekih želatinskih kapsula ili celuloznih kapsula za koje je pogodno da sadrže uljaste tvari.
is a group represented by the formula -NR9R10; 
R* je skupina prikazana formulom -NR*R'"
A 85% solution of 11.3 g of KOH in 150 mL of water is added. 
Doda se 85%-tnu otopinu od 11,3 g KOH u 150 mL vode.
The most abundant IL-18BP isoform, isoform a, exhibits a high affinity for IL-18 with a rapid on-rate and a slow off-rate, and a dissociation constant (Kd) of approximately 0.4 nM (Kim et al. 2000). 
Najčešći je izooblik a, koji ima visoki afinitet za IL-18 s brzim vezanjem i sporim ispuštanjem, a disocijacijska konstanta (Kd) je otprilike 0.4 nM (Kim i sur., 2000).
The AAV vector of any one of claims 1 to 6, wherein the AAV vector comprises a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu AAV vektor obuhvaća replikacijom nedostatan AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova.
31 vessel Process for production of aggregated conformation prion protein from native conformation prion protein by contacting native conformation prion protein with aggregated conformation prion protein in a liquid composition and subjecting the liquid composition to at least one cycle comprising the generation of shear force and a resting phase, characterized in that the shear force is applied to each volume element of the liquid composition and consists of one uniform shear-force intensity having an intensity range of maximally 10% of one shear-force value. 
Postupak proizvodnje prionskog proteina agregirane konformacije iz prionskog proteina nativne konformacije putem dovođenja proteina priona nativne konformacije u kontakt s prionskim proteinom agregirane konformacije u tekućem sastavu i podvrgavanje tekućeg sastava barem jednom ciklusu koji se sastoji od generiranja sile smicanja i faze odmora, naznačeno time da se sila smicanja primjenjuje na svaki element volumena tekućeg sastava 1 sastoji se od jedne uniformne jačine sile smicanja s intenzitetom raspona od maksimalno 10% vrijednosti sile smicanja.
Use of a diaminophenothiazine compound in the manufacture of a medicament for the treatment of mild cognitive impairment (MCI) in a patient suffering therefrom, wherein said compound is selected from compounds of the following formulae: wherein each one of R1, R2, R4, R6, R8, and R9 is independently selected from: 
HR P20191513T1 PATENTNI ZAHTJEVI i. Uporaba diaminofenotiazinskog spoja, naznačena time, da je za proizvodnju lijeka za liječenje blagog kognitivnog poremećaja (BKP) kod pacijenta koji od njega boluje, gdje se navedeni spoj bira od spojeva slijedećih formula:
The method according to claim 1, characterized in that said fixing step (101) comprises an operation for connecting, by gluing, heating and pressing, said first gasket (16), made of waterproof polymeric material, to said assembly insole (15). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se navedena faza pričvršćivanja (101) sastoji od operacije kojom se lijepljenjem, grijanjem 1 prešanjem navedena prva brtva (16), izrađena od vodonepropusnog polimernog materijala, spaja na navedenu temeljnu tabanicu (15).
Ar is selected from the group consisting of phenyl, substituted phenyl, thiophen-yl, substituted thiophen-yl, pyridinyl, substituted pyridinyl, thiazolyl, substituted thiazolyl, pyrimidinyl, substituted pyrimidinyl, furanyl, substituted furanyl, bicyclic aryl, substituted bicyclic aryl, bicyclic heteroaryl, and substituted bicyclic heteroaryl; 
Ar je odabran iz skupine koju čine: fenil, supstituirani fenil, tiofen-il, supstituirani tiofen-il, piridinil, supstituirani piridinil, tiazolil, supstituirani tiazolil, pirimidinil, supstituirani pirimidinil, furanil, supstituirani furanil, biciklički aril, supstituirani biciklički aril, biciklički heteroaril i supstituirani biciklički heteroaril;
An expression vector encoding the antibody of claim 1, comprising a nucleic acid sequence depicted in SEQ ID NO 89, or its conservative sequence variant, or a nucleotide sequence depicted in SEQ ID NO 90, or its conservative sequence variant. 
Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida izabranu iz skupine koja se sastoji od SEQ ID NO:s 64 do 68 i njihovih konzervativnih varijanta sekvenci. Ekspresijski vektor prema zahtjevu 7, koji sadrži sekvencu nukleotida prikazanu u SEQ ID NO 89 i njenu konzervativnu varijantu sekvence.
The method of claim 10, wherein the sensor (240, 291, 292, 293, 294, 295) comprises at least one of a flow sensor, a thermocouple, a pressure sensor, a current sensor (293, 294), a voltage sensor, and a light sensor (295); and wherein the first release device (118) comprises at least one of a heating element, a vibration generator, an ultrasonic transducer, a piezoelectric transducer, and an atomizer. 
Metoda sukladno zahtjevu 10, naznačena time da senzor (240, 291, 292, 293, 294, 295) sadrži barem jedan senzor protoka, termoelement, senzor tlaka, senzor struje (293, 294), senzor napona 1 senzor svjetla (295); i pri čemu uređaj za prvo oslobađanje (118) sadrži barem jedan grijaći element, generator vibracija, ultrazvučni pretvarač, piezoelektrični pretvarač i raspršivač.
The mixture was poured onto crushed ice (300 g) and water (100 ml) added. 
Smjesa se ulije preko smrvljenog leda (300 g) 1 doda se voda (100 ml).
The method according to claim 16, wherein moving the plant along the cutting devices comprises pulling the plant toward the user. 
Postupak prema patentnom zahtjevu 11, naznačen time što se pomicanje biljke duž reznih uređaja sastoji od povlačenja biljke prema korisniku.
a drill pipeline with a drill head provided thereon; 
bušaći cjevovod (13) s bušaćom glavom postavljenom na njemu;
The antibody or antigen-binding fragment thereof according to claim 3, wherein the antibody is a monoclonal antibody selected from the group consisting of a fully human antibody, a humanized antibody and a chimeric antibody. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time što je monoklonsko protutijelo ili njegov antigen-vezujući fragment potpuno ljudsko protutijelo, humanizirano protutijelo, kimerno protutijelo, ili njihov fragment koji veže antigen.
A combination according to claim 9 wherein the anti-neoplastic agent is an inhibitor of serine/threonine kinases. 
Kombinacija u skladu s patentnim zahtjevom 9, naznačena time što je antineoplastično sredstvo inhibitor serinsko-treoninskih kinaza.
The compound as recited in any one or more of claims 1 to 5, wherein n is 3 and said compound contains a a-phosphorothioate group, or wherein n is 4 and said compound contains a Y-phosphorothioate group; and wherein said compound is not hydrolyzed by Dcp2 under physiological conditions. 
Tvar kako je nabrojena u jednom ili više od patentnih zahtjeva 1 do 5, pri čemu je n 3 i navedena tvar sadrži a-fosfortioatnu grupu, ili pri čemu je n 4 i navedena tvar sadrži Y- fosfortioatnu grupu; i pri čemu navedena tvar nije hidrolizirana s Dcp2 pod fiziološkim uvjetima.
wherein the halogen is a halogen atom selected from fluorine, chlorine, bromine and iodine; 
"halogen" jest atom halogena odabran od sljedećih: fluor, klor, brom te jod;
The dsRNA for use of claim 1 or 2, wherein the dsRNA further comprising a ligand. 
Dvolančana ribonukleinska kiselina (dsRNA) za inhibiciju ekspresije ALAS1, naznačena time da dsRNA sadrži:
Therefore such wall element may be sized up to a length of 5 or 6 meters or more. 
Zbog toga se takav zidni element može izraditi do duljine od 5 ili 6 metara ili više.
The method of Claim 15, wherein said parent bacterial strain is a strain obtained from a culture selected from starter cultures, probiotic cultures, and dietary supplement cultures. 
Postupak prema zahtjevu 15, naznačen time da navedeni matični bakterijski soj je soj dobiven iz kulture koja je odabrana od starter kultura, probiotičkih kultura, te kultura dodataka prehrani.
wherein the pH of the topical gel composition is adjusted to 5.0 to 6.5 by an adequate amount of sodium hydroxide aqueous solution. 
pri čemu je pH kompozicije topičkog gela podešen na 5,0 do 6,5 adekvatnom količinom vodene otopine natrijum hidroksida.
A pharmaceutical composition comprising ET-743 in combination with a pharmaceutically acceptable carrier, diluent or excipient is claimed in U.S. Pat. 
Farmaceutska smjesa koja sadrži ET-743 u kombinaciji s farmaceutski prihvatljivim nosačem, otapalom ili inertnim puniocem navodi se u US 5,256,663.
The method according to any one of the preceding claims, wherein the saturated temperature of the excess steam (7) and the saturated temperature of the compressed excess steam (8) differs by a temperature difference ATE, wherein ATE is from 6 to 130°C, preferably from 11 to 80°C, more preferably from 15 to 60°C, and most preferably from 20 to 45°C. 
Postupak u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da se zasićena temperatura viška pare (7) i zasićena temperatura komprimiranog viška pare (8) razlikuje temperaturnom razlikom ATE, pri čemu je ATE od 6 do 130°C, poželjno 11 do 80°C, poželjnije od 15 do 60°C i najpoželjnije od 20 do 45°C.
An antibody for use of any one of claims 1-13, a conjugate for use of claim 15 or a pharmaceutical composition of claim 16, for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18A2. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 20, konjugat prema patentnom zahtjevu 22 ili farmaceutska kompozicija prema patentnom zahtjevu 23 za uporabu u postupku liječenja ili prevencije bolesti ili poremećaja koja/koji uključuje stanice koje eksprimiraju CLD18A2.
80% to 95% by weight of polyethylene glycol; 
80% do 95 masenih % polietilen glikola; ii.
oil in water adjuvants, water-in-oil adjuvants, immunostimulating complex (ISCOMs), liposomes, formulated nano and micro-particles; and 
adjuvansi ulje-u-vodi, adjuvansi voda-u-ulju, imunostimulirajuci kompleks (ISKOMS), liposomi, formulirane nano i mikro-čestice; i
The collection according to claim 1, wherein said antibodies or fragments thereof comprise a FR4 region selected from the group consisting of JH4 (SEQ ID NO:293), Jk1 (SEQ ID NO:297), and Jλ2/3 (SEQ ID NO:301). 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena protutijela, ili njihovi funkcionalni fragmenti, sadrže područje FR4, koje se bira iz skupine koju čine JH4, Jk1, i JX2/3, čiji su sljedovi definirani na slici 40.
A plant or plant part, comprising one or more exogenous sequences integrated into the Zp15 locus by the method of claim 1 . 
Biljka ili dio biljke, naznačen/a time, da obuhvaća jednu ili više egzogenih sekvenci integriranih u Zp15-lokus pomoću postupka u skladu sa zahtjevom 1.
Exemplification of the invention: 
(54) Naziv izuma:
with a compound of formula XXVI 
Xi reagira sa spojem formule XXVI ij
contacting the antigen presenting cells of step (iii) with T-cells to evaluate the ability of the peptide to stimulate the T-cells; and 
stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; i